ResMed (ASX: RMD and NYSE: RMD) is a leading developer, manufacturer and marketer of products for the screening, treatment and long-term management of sleep-disordered breathing (SDB) and other respiratory disorders.
- Formed in 1989
- Primary purpose was to commercialize a device for treating obstructive sleep apnea (OSA), the most common type of SDB*
- We have maintained our focus on SDB. There is greater public and physician awareness
- Operations have grown dramatically via the introduction of highly innovative product lines
- We operate in more than 70 countries via direct offices and a network of distributors
*Nasal continuous positive airway pressure (CPAP) therapy was developed in 1981 by Professor Colin Sullivan and colleagues (University of Sydney, Australia) and provided the first successful non-invasive treatment of OSA.